Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer

Table 3

Previous case reports of patients with mCRC and severe liver dysfunction treated with FOLFOX (reprinted with permission from JNCCN, Journal of the National Comprehensive Cancer Network [7]).

Age (y), sex	mFOLFOX6 (each drug dose: mg/m^2)		Total bilirubin (mg/dL)		CEA (ng/mL)		Response	FOLFOX cycles until disease progression
	1st cycle progression^a	2nd cycle^a	Baseline	After 2 cycles	Baseline	After 2 cycles
Case  1: 63, M [6]	Bolus 5-FU: 300, IV 5-FU: 1800, LV: 200, Ox: 60	Bolus 5-FU: 400, IV 5-FU: 240, LV: 400, Ox: 85	3.5	1.2	188.0	4.8	PR	14
Case  2: 59, F [6]	Bolus 5-FU: 0, IV 5-FU: 2000, LV: 400, Ox: 65	Bolus 5-FU: 0, IV 5-FU: 2400, LV: 400, Ox: 85	5.9	2.1	1.3	895.0	SD	8
Case  3: 37, F [6]	Bolus 5-FU: 0, IV 5-FU: 200, LV: 400, Ox: 85	Bolus 5-FU: 400, IV 5-FU: 2400, LV: 400, Ox: 85	4.2	2.1	3685.0	937.0	PR	≥10
Case  4: 67, M [7]	Bolus 5-FU: 200, IV 5-FU: 1200, LV: 200, Ox: 75	Bolus 5-FU: 200, IV 5-FU: 1200, LV: 200, Ox: 75	9.4	2.4	12.2	4.0	PR	21
Case  5: 58, F [8]	Bolus 5-FU: 0, IV 5-FU: 2400, L-LV: 200, Ox: 85	Bolus 5-FU: 400, IV 5-FU: 2400, L-LV: 200, Ox: 85	3.9	2.2	103.1	96.0	SD	6

CEA: carcinoembryonic antigen; F: female; FOLFOX: 5-FU, leucovorin, and oxaliplatin; IV: infusional; L-LV: levoleucovorin; LV: leucovorin; M: male; Ox: oxaliplatin; PR: partial response; SD: stable disease.
^aBolus 5-FU, infusional 5-FU, LV, and oxaliplatin.